Tubize-Fin - Asset Resilience Ratio
Tubize-Fin (TUB) has an Asset Resilience Ratio of 0.05% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Tubize-Fin balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Tubize-Fin's Asset Resilience Ratio has changed over time. See TUB book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Tubize-Fin's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Tubize-Fin.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €900.00K | 0.05% |
| Total Liquid Assets | €900.00K | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Tubize-Fin maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tubize-Fin Industry Peers by Asset Resilience Ratio
Compare Tubize-Fin's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merus BV
NASDAQ:MRUS |
Biotechnology | 29.69% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 76.71% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 9.59% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Tubize-Fin (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Tubize-Fin.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.05% | €900.00K ≈ $1.05 Million |
€1.93 Billion ≈ $2.26 Billion |
-46.12pp |
| 2021-12-31 | 46.17% | €1.51 Billion ≈ $1.76 Billion |
€3.27 Billion ≈ $3.82 Billion |
+43.14pp |
| 2013-12-31 | 3.03% | €54.65 Million ≈ $63.90 Million |
€1.80 Billion ≈ $2.11 Billion |
+2.43pp |
| 2004-12-31 | 0.60% | €4.30 Million ≈ $5.03 Million |
€715.25 Million ≈ $836.21 Million |
+0.54pp |
| 2003-12-31 | 0.06% | €500.00K ≈ $584.55K |
€791.03 Million ≈ $924.80 Million |
-0.01pp |
| 2002-12-31 | 0.07% | €530.00K ≈ $619.63K |
€748.11 Million ≈ $874.61 Million |
-- |
About Tubize-Fin
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affect the immune system or the central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.